"Regeneron said patients given the treatment, REGN-COV2, made around 57% fewer Covid-19 related medical visits than those given a placebo over a 29 day period.
The drop was around 72% in patients with one or more risk factors such as being over age 50, obesity, cardiovascular, metabolic, lung, liver or kidney disease, or an immunocompromised status.
Last month, the company released early data from the trial showing the treatment reduced viral levels and improved symptoms in non-hospitalized Covid-19 patients. The new data confirm the initial findings, the company said."
"Regeneron said earlier this month it had around 50,000 doses of its treatment ready for distribution."
www.cnbc.com
The drop was around 72% in patients with one or more risk factors such as being over age 50, obesity, cardiovascular, metabolic, lung, liver or kidney disease, or an immunocompromised status.
Last month, the company released early data from the trial showing the treatment reduced viral levels and improved symptoms in non-hospitalized Covid-19 patients. The new data confirm the initial findings, the company said."
"Regeneron said earlier this month it had around 50,000 doses of its treatment ready for distribution."

Regeneron says its Covid-19 antibody treatment cut medical visits in trial
Regeneron Pharmaceuticals said on Wednesday its coronavirus antibody cocktail significantly reduced medical visits in a trial of nearly 800 patients.